News und Analysen
EQS-News: M1 Kliniken AG: Market leader for beauty medicine in Germany opens up in the 9th foreign market and prepares market entry in the USA
Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the “Company”), announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-News: M1 Kliniken AG publishes figures for the first half year 2023:
EQS-News: Vita 34 stabilizes business development in the second quarter and noticeably improves earnings
Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA™ (ACER-001) with Acer Therapeutics
Poxel Reports Cash and Revenue for the Second Quarter and First Half 2023 and Provides Corporate Update
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended
Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to two upcoming webcasts of Pfizer discussions at healthcare conferences:
-
Annaliesa Anderson, SVP & Head
Convatec Group PLC: TR-1 Notification of Major Holdings
Dexcom Announces Upcoming Conference Presentations
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences:
-
Jereme Sylvain, Executive Vice President and
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
EQS-News: BRAIN Biotech AG reports solid 9M numbers despite ongoing high R&D investments and more challenging economic conditions
EQS-News: Formycon reports successful first half of 2023
Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Novocure (NASDAQ: NVCR) announced today that data from the randomized phase 3 LUNAR clinical trial evaluating the use of Tumor Treating Fields (TTFields) therapy together with standard systemic
EQS-News: Formycon announces File Acceptance for FYB203, a biosimilar candidate to Eylea®1 (aflibercept), by the U.S. Food and Drug Administration (FDA)
QuidelOrtho to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion
Dexcom Appoints Rimma Driscoll to Board of Directors
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Rimma Driscoll to its Board of Directors, effective August 24, 2023.
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer
Novocure (NASDAQ: NVCR) today announced that the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of Tumor Treating Fields (TTFields) together with paclitaxel in patients with
Uni-Bio Science Group Limited Announces 2023 Interim Results
Convatec Group PLC: Scrip Dividend – Calculation Price
Novocure to Participate in Upcoming Investor Conferences
Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences. William Doyle, Novocure’s Executive Chairman, and Ashley Cordova, Novocure’s Chief
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC